N-Acetyl Cysteine (NAC) 用于 幽门螺杆菌感染
C 证据 来自小型研究的证据有限，但存在一些积极信号。NAC（600至1,200毫克/日）可能通过破坏生物膜提高幽门螺杆菌根除率。小规模研究显示与标准疗法联合使用时根除率提高。
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dn\u002Dacetyl\u002Dcysteine\u0026condition\u003Dh\u002Dpylori';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
结论
NAC（600至1,200毫克/日）可能通过破坏生物膜提高幽门螺杆菌根除率。小规模研究显示与标准疗法联合使用时根除率提高。
Key Study Findings
In Vitro
Berberrubine inhibits Helicobacter pylori by inducing oxidative stress and impairing membrane integrity.
Dose: MIC 11 μg/mL
vs: None
Outcome: anti-Helicobacter pylori activity
效果: None
None
研究人群: None
Other
Correction to "N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter …
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: Published erratum (correction notice)
Review
Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: None
Other
Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy.
Dose: None
vs: None
Outcome: Cancer outcomes
效果: None
None
研究人群: Cancer patients
In Vitro
Helicobacter pylori infection selectively attenuates endothelial function in male mice via exosomes-mediated ROS production.
Dose: None
vs: None
Outcome: choline levels/cognition
效果: None
None
研究人群: Mice
Other
α-Lipoic Acid Inhibits Apoptosis by Suppressing the Loss of Ku Proteins in Helicobacter pylori-Infected Human …
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: None
Key Statistics
3
研究数量
250
受试者
↑
Positive
C
等级
Referenced Papers
mLife
2026
Biochimica et biophysica …
2025
1 次引用
Oxidative medicine and …
2025
Pharmaceutics
2024
8 次引用
Frontiers in cellular …
2023
7 次引用
Frontiers in cardiovascular …
2022
27 次引用
Nutrients
2022
11 次引用
Microbial drug resistance …
2020
34 次引用
Therapeutic advances in …
2020
7 次引用
Synthesis of Fucose Derivatives with Thiol Motifs towards Suicide Inhibition of Helicobacter pylori.
Other
Molecules (Basel, Switzerland)
2020
Expert review of …
2019
85 次引用
The Cochrane database …
2019
21 次引用
Oxidative medicine and …
2018
93 次引用
The effect of antioxidants on Helicobacter pylori eradication: A systematic review with meta-analysis.
Meta-Analysis
Helicobacter
2018
18 次引用
N-acetylcysteine prevents the development of gastritis induced by Helicobacter pylori infection.
Other
Journal of microbiology …
2017
16 次引用
Cell host & …
2016
101 次引用
Helicobacter
2016
60 次引用
Nutrition research (New …
2016
25 次引用
Molecular carcinogenesis
2016
18 次引用
Gut and liver
2016
17 次引用
Pathogens and disease
2015
64 次引用
World journal of …
2015
21 次引用
Journal of cancer …
2013
10 次引用
Alimentary pharmacology & …
2012
104 次引用
Clinical and experimental …
2012
1 次引用
Journal of clinical …
2011
34 次引用
Clinical gastroenterology and …
2010
103 次引用
Pharmaceutical biology
2010
16 次引用
Probiotics and antimicrobial …
2010
9 次引用
American family physician
2009
Helicobacter
2007
130 次引用
World journal of …
2007
77 次引用
Journal of agricultural …
2007
44 次引用
American journal of …
2007
11 次引用
Digestive diseases and …
2004
53 次引用
Digestive diseases and …
2004
4 次引用
Digestive diseases and …
2003
69 次引用
Annals of the …
2002
30 次引用
Journal of environmental …
2002
Pharmacological research
2001
25 次引用
Schweizerische medizinische Wochenschrift
1994
22 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 600-1,200 mg/day in divided doses
- hpyloriadjunct:
- 600 mg twice daily alongside standard triple therapy
- antioxidantsupport:
- 600-900 mg/day
上限： Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| MIC 11 μg/mL | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Negative | -- |
| None | -- | Positive | -- |
最佳服用时间： With or without food; divide doses throughout the day
Safety & Side Effects
已报告的副作用
- ⚠ Nausea and vomiting (most common, especially at higher doses)
- ⚠ Diarrhea
- ⚠ Unpleasant sulfur taste/odor
- ⚠ Headache
已知相互作用
- ● Nitroglycerin (NAC may enhance vasodilatory effects; risk of hypotension)
- ● Activated charcoal (may reduce NAC absorption)
- ● Anticoagulants (NAC may have mild antiplatelet effects)
- ● ACE inhibitors (additive hypotensive effect with nitroglycerin combination)
可耐受最高摄入量： Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does N-Acetyl Cysteine (NAC) help with 幽门螺杆菌感染?
Based on 3 studies with 250 participants, there is limited but promising evidence that N-Acetyl Cysteine (NAC) may support 幽门螺杆菌感染 management. Our evidence grade is C (Some Evidence).
How much N-Acetyl Cysteine (NAC) should I take for 幽门螺杆菌感染?
Studies have used various dosages. A commonly studied range is 600-1,200 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of N-Acetyl Cysteine (NAC)?
Reported side effects may include Nausea and vomiting (most common, especially at higher doses), Diarrhea, Unpleasant sulfur taste/odor, Headache. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for N-Acetyl Cysteine (NAC) and 幽门螺杆菌感染?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 250 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 幽门螺杆菌感染
N-Acetyl Cysteine (NAC) 用于其他健康状况
References
- [1] Minzhi Jiang et al.. mLife. 2026. Berberrubine inhibits Helicobacter pylori by inducing oxidative stress and impairing membrane integrity. doi:10.1002/mlf2.70061 PubMed
- [2] Wei Li et al.. Biochim Biophys Acta Rev Cancer. 2025. Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis. doi:10.1016/j.bbcan.2025.189492 PubMed
- [3] . Oxid Med Cell Longev. 2025. Correction to "N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter pylori Infection". doi:10.1155/omcl/9794537 PubMed
- [4] Muhammad Irfan Alam et al.. Pharmaceutics. 2024. Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy. doi:10.3390/pharmaceutics16091123 PubMed
- [5] Linfang Zhang et al.. Front Cell Infect Microbiol. 2023. Helicobacter pylori infection selectively attenuates endothelial function in male mice via exosomes-mediated ROS production. doi:10.3389/fcimb.2023.1142387 PubMed
- [6] Xiujuan Xia et al.. Front Cardiovasc Med. 2022. CagA+ Helicobacter pylori, Not CagA- Helicobacter pylori, Infection Impairs Endothelial Function Through Exosomes-Mediated ROS Formation. doi:10.3389/fcvm.2022.881372 PubMed
- [7] Dayong Park et al.. Nutrients. 2022. α-Lipoic Acid Inhibits Apoptosis by Suppressing the Loss of Ku Proteins in Helicobacter pylori-Infected Human Gastric Epithelial Cells. doi:10.3390/nu14153206 PubMed
- [8] Yuanna Shen et al.. Microb Drug Resist. 2020. Activity of Sodium Lauryl Sulfate, Rhamnolipids, and N-Acetylcysteine Against Biofilms of Five Common Pathogens. doi:10.1089/mdr.2018.0385 PubMed
- [9] Chieh-Chang Chen et al.. Therap Adv Gastroenterol. 2020. Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized … doi:10.1177/1756284820927306 PubMed
- [10] Mark Reihill et al.. Molecules. 2020. Synthesis of Fucose Derivatives with Thiol Motifs towards Suicide Inhibition of Helicobacter pylori. doi:10.3390/molecules25184281 PubMed
- [11] Lyudmila Boyanova et al.. Expert Rev Clin Pharmacol. 2019. Multidrug resistance in Helicobacter pylori: current state and future directions. doi:10.1080/17512433.2019.1654858 PubMed
- [12] Luís Eduardo S Fontes et al.. Cochrane Database Syst Rev. 2019. N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication. doi:10.1002/14651858.CD012357.pub2 PubMed
- [13] Chuan Xie et al.. Oxid Med Cell Longev. 2018. N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter pylori Infection. doi:10.1155/2018/1874985 PubMed
- [14] Yao-Bin Yang-Ou et al.. Helicobacter. 2018. The effect of antioxidants on Helicobacter pylori eradication: A systematic review with meta-analysis. doi:10.1111/hel.12535 PubMed
- [15] Sungil Jang et al.. J Microbiol. 2017. N-acetylcysteine prevents the development of gastritis induced by Helicobacter pylori infection. doi:10.1007/s12275-017-7089-9 PubMed
- [16] Kristof Moonens et al.. Cell Host Microbe. 2016. Structural Insights into Polymorphic ABO Glycan Binding by Helicobacter pylori. doi:10.1016/j.chom.2015.12.004 PubMed
- [17] Juan-Yu Piao et al.. Helicobacter. 2016. Helicobacter pylori Activates IL-6-STAT3 Signaling in Human Gastric Cancer Cells: Potential Roles for Reactive Oxygen Species. doi:10.1111/hel.12298 PubMed
- [18] Aryoung Kim et al.. Nutr Res. 2016. Supplementation with Angelica keiskei inhibits expression of inflammatory mediators in the gastric mucosa of Helicobacter pylori-infected mice. doi:10.1016/j.nutres.2015.12.017 PubMed
- [19] Hoang-Kieu-Chi Ngo et al.. Mol Carcinog. 2016. Helicobacter pylori induces Snail expression through ROS-mediated activation of Erk and inactivation of GSK-3β in human gastric cancer cells. doi:10.1002/mc.22464 PubMed
- [20] Hyuk Yoon et al.. Gut Liver. 2016. Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. doi:10.5009/gnl15048 PubMed
- [21] Xiang Li et al.. Pathog Dis. 2015. Helicobacter pylori induces IL-1β and IL-18 production in human monocytic cell line through activation of NLRP3 inflammasome via ROS signaling … doi:10.1093/femspd/ftu024 PubMed
- [22] Fatih Ermis et al.. World J Methodol. 2015. Current Helicobacter pylori treatment in 2014. doi:10.5662/wjm.v5.i2.101 PubMed
- [23] Minkyung Bae et al.. J Cancer Prev. 2013. Oxidative DNA Damage Response in Helicobacter pylori-Infected Mongolian Gerbils. doi:10.15430/jcp.2013.18.3.271 PubMed
- [24] G Cammarota et al.. Aliment Pharmacol Ther. 2012. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. doi:10.1111/j.1365-2036.2012.05165.x PubMed
- [25] Riccardo Urgesi et al.. Clin Exp Gastroenterol. 2012. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. doi:10.2147/CEG.S25416 PubMed
- [26] Kian Makipour et al.. J Clin Gastroenterol. 2011. The potential role of N-acetylcysteine for the treatment of Helicobacter pylori. doi:10.1097/MCG.0b013e31822be4d6 PubMed
- [27] Giovanni Cammarota et al.. Clin Gastroenterol Hepatol. 2010. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. doi:10.1016/j.cgh.2010.05.006 PubMed
- [28] Thomas Sawidis et al.. Pharm Biol. 2010. Chios mastic, a natural supplement for zinc to enhance male sexuality and prostate function. doi:10.3109/13880200903029399 PubMed
- [29] Luc De Vuyst et al.. Probiotics Antimicrob Proteins. 2010. Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori. doi:10.1007/s12602-009-9029-4 PubMed
- [30] Paul J Millea. Am Fam Physician. 2009. N-acetylcysteine: multiple clinical applications. PubMed
- [31] Francesco Di Mario et al.. Helicobacter. 2007. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? doi:10.1111/j.1523-5378.2007.00497.x PubMed
- [32] Chun-Chao Chang et al.. World J Gastroenterol. 2007. Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, prospective, randomized study. doi:10.3748/wjg.v13.i3.444 PubMed
- [33] Gabriel A Agbor et al.. J Agric Food Chem. 2007. Effect of selenium- and glutathione-enriched yeast supplementation on a combined atherosclerosis and diabetes hamster model. doi:10.1021/jf0711901 PubMed
- [34] Breda M Walsh et al.. Am J Physiol Cell Physiol. 2007. Thiol-oxidant monochloramine mobilizes intracellular Ca2+ in parietal cells of rabbit gastric glands. doi:10.1152/ajpcell.00189.2006 PubMed
- [35] Hien Quoc Huynh et al.. Dig Dis Sci. 2004. N-acetylcysteine, a novel treatment for Helicobacter pylori infection. doi:10.1007/s10620-004-9583-2 PubMed
- [36] Geoffrey M Matthews et al.. Dig Dis Sci. 2004. Cellular mucosal defense is attenuated with chronicity of Helicobacter pylori infection. doi:10.1023/b:ddas.0000037796.64430.f6 PubMed
- [37] Sang Hui Chu et al.. Dig Dis Sci. 2003. Role of NF-kappaB and AP-1 on Helicobater pylori-induced IL-8 expression in AGS cells. doi:10.1023/a:1021963007225 PubMed
- [38] Jeong Yeon Seo et al.. Ann N Y Acad Sci. 2002. Transcriptional regulation by thiol compounds in Helicobacter pylori-induced interleukin-8 production in human gastric epithelial cells. doi:10.1111/j.1749-6632.2002.tb04697.x PubMed
- [39] Hyeyoung Kim et al.. J Environ Pathol Toxicol Oncol. 2002. Oxidant-sensitive transcription factor and cyclooxygenase-2 by Helicobacter pylori stimulation in human gastric cancer cells. PubMed
- [40] W S Hong et al.. Pharmacol Res. 2001. The antioxidant effect of rebamipide on oxygen free radical production by H. pylori-activated human neutrophils: in comparison with N-acetylcysteine, ascorbic … doi:10.1006/phrs.2001.0839 PubMed
- [41] G Zala et al.. Schweiz Med Wochenschr. 1994. [Omeprazole/amoxicillin: improved eradication of Helicobacter pylori in smokers because of N-acetylcysteine]. PubMed
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。